Andrew Larry Frelinger III on Activation of Platelets in Flow Cytometry
Andrew Larry Frelinger III, Director Emeritus, Center for Platelet Research Studies Corresponding Faculty, Dept. of Pediatrics at Harvard Medical School, shared on LinkedIn:
”I am very pleased to share this publication which came about through a great collaboration with the Steve Watson lab.
The paper explores activation of GPVI, CLEC-2 and PEAR1 using multivalent nanobodies.
Special thanks to Rachel Lamerton for spearheading the work, Elenya Martin for preparing the nanobodies, and Jax Perry for the performing and analyzing the spectral cytometry assays.
These fantastic tools may aid in the development of assays to assess platelet function disorders.
Enjoy!”
Read the full article in RPTH.
Article: A minimum valency of 4 is required for robust activation of platelets in flow cytometry by multivalent nanobodies to Glycoprotein VI, C-type lectin-like receptor 2 and Platelet Endothelial Aggregation Receptor 1
Authors: Rachel E. Lamerton, Eleyna M. Martin, Jacqueline Perry, Adam F. Cunningham, Steve P. Watson, Andrew Larry Frelinger III
Stay updated on all scientific advances with Hemostasis Today.
-
May 6, 2026, 13:16Mehari Gebreyohanns: Transition from Alteplase to Tenecteplase Is Full Steam Ahead in Texas
-
May 6, 2026, 12:53Masoabi Sefojane: In Africa 88% of Hemophilia Remains Undiagnosed
-
May 6, 2026, 12:36Alan Nurden: CRISPR-Mediated Megakaryocyte Modeling in Glanzmann Thrombasthenia
-
May 6, 2026, 12:12Mona Ranade: Insights from a Medeloop Analytics Study Evaluate Catheter-Directed Therapy in Pulmonary Embolism
-
May 6, 2026, 11:50Natalie L. Baggio: A 24/7 Neurointerventional Stroke Care at Corewell Health Is Now a Reality
-
May 6, 2026, 11:30Paula Caporal: Consensus on the Diagnosis and Management of Pediatric Stroke in Argentina
-
May 6, 2026, 11:14Li Khim Kwah: Proud for the Development of The New Singapore Stroke Rehabilitation Guideline
-
May 6, 2026, 10:55Hugo Antonio Romo Rubio: A New Paradigm in Treatment for Hemophilia A from FRONTIERS2 Phase 3 Study
-
May 6, 2026, 10:40Ifeanyichukwu Ifechidere: Why INR Can Be Dangerously Misleading